327 related articles for article (PubMed ID: 24634469)
21. Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics.
Glorikian H; Warburg RJ; Moore K; Malinowski J
Expert Opin Ther Pat; 2018 Feb; 28(2):123-128. PubMed ID: 29224409
[TBL] [Abstract][Full Text] [Related]
22. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
23. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.
Parkinson DR; McCormack RT; Keating SM; Gutman SI; Hamilton SR; Mansfield EA; Piper MA; Deverka P; Frueh FW; Jessup JM; McShane LM; Tunis SR; Sigman CC; Kelloff GJ
Clin Cancer Res; 2014 Mar; 20(6):1428-44. PubMed ID: 24634466
[TBL] [Abstract][Full Text] [Related]
24. Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology.
Gibbs JN
Expert Rev Mol Diagn; 2011 May; 11(4):367-81. PubMed ID: 21545255
[TBL] [Abstract][Full Text] [Related]
25. Companion and complementary diagnostics: an important treatment decision tool in precision medicine.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):557-559. PubMed ID: 32342707
[No Abstract] [Full Text] [Related]
26. Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing.
Ferreira CG; Achatz MI; Ashton-Prolla P; Begnami MD; Marchini FK; Stefani SD
Lancet Oncol; 2016 Aug; 17(8):e363-e370. PubMed ID: 27511160
[TBL] [Abstract][Full Text] [Related]
27. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
28. Developing precision medicine in a global world.
Rubin EH; Allen JD; Nowak JA; Bates SE
Clin Cancer Res; 2014 Mar; 20(6):1419-27. PubMed ID: 24634465
[TBL] [Abstract][Full Text] [Related]
29. Companion Diagnostics and Molecular Imaging.
Puranik AD; Kulkarni HR; Baum RP
Cancer J; 2015; 21(3):213-7. PubMed ID: 26049701
[TBL] [Abstract][Full Text] [Related]
30. Implementing the EU in vitro diagnostic regulation - a European regulatory perspective on companion diagnostics.
Ritzhaupt A; Hayes I; Ehmann F
Expert Rev Mol Diagn; 2020 Jun; 20(6):565-567. PubMed ID: 31976775
[No Abstract] [Full Text] [Related]
31. Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency.
Maliepaard M; Nibi P; Nibi G; Pasmooij AMG
Front Med (Lausanne); 2022; 9():893028. PubMed ID: 35602486
[TBL] [Abstract][Full Text] [Related]
32. Use of botanicals in food supplements. Regulatory scope, scientific risk assessment and claim substantiation. 2005.
Coppens P; Delmulle L; Gulati O; Richardson D; Ruthsatz M; Sievers H; Sidani S;
Ann Nutr Metab; 2006; 50(6):538-54. PubMed ID: 17191027
[TBL] [Abstract][Full Text] [Related]
33. Will children with cancer benefit from the new European Paediatric Medicines Regulation?
Vassal G
Eur J Cancer; 2009 Jun; 45(9):1535-46. PubMed ID: 19419857
[TBL] [Abstract][Full Text] [Related]
34. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
Fears R; Kaufmann S; Ter Meulen V; Zumla A;
Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566
[TBL] [Abstract][Full Text] [Related]
35. New European Union Regulations Related to Whole Slide Image Scanners and Image Analysis Software.
García-Rojo M; De Mena D; Muriel-Cueto P; Atienza-Cuevas L; Domínguez-Gómez M; Bueno G
J Pathol Inform; 2019; 10():2. PubMed ID: 30783546
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacogenomics].
Nakatani K; Nobori T
Rinsho Byori; 2013 Nov; 61(11):1018-25. PubMed ID: 24450107
[TBL] [Abstract][Full Text] [Related]
37. [Discussing the usefulness of companion diagnostics - introductory remarks by chairpersons].
Nobori T; Nomura F
Rinsho Byori; 2014 Dec; 62(12):1263-4. PubMed ID: 25823244
[TBL] [Abstract][Full Text] [Related]
38. Companion Diagnostics: State of the Art and New Regulations.
Valla V; Alzabin S; Koukoura A; Lewis A; Nielsen AA; Vassiliadis E
Biomark Insights; 2021; 16():11772719211047763. PubMed ID: 34658618
[TBL] [Abstract][Full Text] [Related]
39. Mutual Recognition of the Food and Drug Administration and European Community Member State Conformity Assessment Procedures; pharmaceutical GMP inspection reports, medical device quality system evaluation reports, and certain medical device premarket evaluation reports--FDA. Proposed rule.
Fed Regist; 1998 Apr; 63(69):17744-71. PubMed ID: 10177764
[TBL] [Abstract][Full Text] [Related]
40. Understanding medical device regulation.
Galgon RE
Curr Opin Anaesthesiol; 2016 Dec; 29(6):703-710. PubMed ID: 27585362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
